Mesoblast Limited (ASX:MSB, Nasdaq:MESO) reported net sales of US$30.3 million for its FDA-approved cellular therapy Ryoncil in the March quarter, bringing total revenue since launch close to US$100 million. Strong sales in February and March offset January’s seasonal dip.
- Ryoncil net sales reached US$30.3 million in Q1 2026
- Total revenue since launch approaches US$100 million
- Strong sales in February and March offset January seasonality
- Revenue supports Mesoblast’s balance sheet and late-stage programs
- Inaugural R&D Day scheduled for April 8, 2026, to outline growth strategy
Ryoncil Sales Performance in Q1 2026
Mesoblast Limited (ASX:MSB, Nasdaq:MESO), a biotechnology company specialising in allogeneic cellular medicines, announced that its lead product Ryoncil (remestemcel-L-rknd) generated net sales of US$30.3 million in the quarter ended 31 March 2026. The company noted that strong sales in February and March helped offset the typical seasonality-related slowdown observed in January.
This quarterly performance brings the total net revenue from Ryoncil since its launch to nearly US$100 million, according to management’s initial analysis. These figures remain subject to completion of Mesoblast’s financial closing procedures and audit.
Product and Market Context
Ryoncil is the first mesenchymal stromal cell (MSC) therapy approved by the U.S. Food and Drug Administration (FDA) for any indication. It is specifically authorised for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in paediatric patients aged two months and older, representing a niche but critical market segment.
Mesoblast highlighted that the revenue generated from Ryoncil strengthens its balance sheet and underpins ongoing label extension efforts and late-stage clinical programs. The company is developing Ryoncil for additional inflammatory diseases, including adult SR-aGvHD and biologic-resistant inflammatory bowel disease. Additionally, its rexlemestrocel-L platform is being advanced for heart failure and chronic low back pain.
Upcoming R&D Day and Strategic Outlook
Mesoblast plans to host its inaugural R&D Day on 8 April 2026 in New York City, with a live webcast available globally. The event will feature presentations from senior leadership and key opinion leaders, focusing on the growth strategy for Ryoncil and updates on the company’s broader late-stage product pipeline.
Chief Executive Dr Silviu Itescu commented, "Revenue for Ryoncil continues to be impressive. We will outline our growth strategy for Ryoncil as well as our robust late-stage product pipeline at our inaugural R&D event this week." The webcast can be accessed via the company’s website.
Intellectual Property and Manufacturing Capabilities
Mesoblast holds a substantial intellectual property portfolio with over 1,000 granted patents and applications covering mesenchymal stromal cell compositions, manufacturing methods, and indications. These protections extend through at least 2044 in major markets, providing a commercial moat for its cell therapy products.
The company’s proprietary manufacturing processes enable industrial-scale production of cryopreserved, off-the-shelf cellular medicines, designed to be readily available worldwide. Mesoblast operates facilities in Australia, the United States, and Singapore.
Regulatory and Forward-Looking Considerations
Mesoblast’s announcement includes standard forward-looking statements highlighting risks and uncertainties typical of biotechnology companies, including clinical development progress, regulatory approvals, market acceptance, and financial performance. The company cautions that actual results may differ materially from expectations.
Investors and analysts are advised to consider these factors alongside the upcoming R&D Day webcast for a more detailed understanding of Mesoblast’s commercial and clinical outlook.
Bottom Line?
Mesoblast’s Ryoncil sales momentum in Q1 2026 underscores ongoing commercial traction, though future growth will depend on successful label expansions and pipeline progress.
Questions in the middle?
- How will Mesoblast’s growth strategy for Ryoncil address competitive and market access challenges?
- What are the timelines and prospects for Ryoncil’s label extensions and new indications?
- How might the outcomes of late-stage clinical programs impact Mesoblast’s financial outlook and valuation?